Diagnosing age-related macular degeneration (AMD) at its earliest subclinical stage allows you to proactively slow progression of the disease with intervention strategies.
Dark adaptation testing with the AdaptDx Pro guided by Theia:
Highly accurate – 90.6% sensitive to identifying AMD cases and 90.5% specific to identifying normal cases.
Subclinical detection – helps you diagnose AMD at least three years before drusen are clinically visible
Scientifically proven – backed by over 40 peer-reviewed publications
AdaptDx Pro combines the game-changing science of dark adaptation
testing with patient comfort and convenience.